Compile Data Set for Download or QSAR
Report error Found 183 Enz. Inhib. hit(s) with all data for entry = 7700
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212110(US9290485, 142)
Affinity DataIC50: 0.0224nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212116(US9290485, 148)
Affinity DataIC50: 0.0300nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212114(US9290485, 146)
Affinity DataIC50: 0.0400nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM211977(US9290485, 9)
Affinity DataIC50: 0.0912nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212115(US9290485, 147)
Affinity DataIC50: 0.100nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212136(US9290485, 168)
Affinity DataIC50: 0.100nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212004(US9290485, 36)
Affinity DataIC50: 0.134nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM211974(US9290485, 6)
Affinity DataIC50: 0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212113(US9290485, 145)
Affinity DataIC50: 0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212134(US9290485, 166)
Affinity DataIC50: 0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212135(US9290485, 167)
Affinity DataIC50: 0.200nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212141(US9290485, 173)
Affinity DataIC50: 0.400nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212124(US9290485, 156)
Affinity DataIC50: 0.920nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212109(US9290485, 141)
Affinity DataIC50: 1.20nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212122(US9290485, 154)
Affinity DataIC50: 2nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212125(US9290485, 157)
Affinity DataIC50: 2nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212062(US9290485, 94)
Affinity DataIC50: 2.10nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212111(US9290485, 143)
Affinity DataIC50: 2.60nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212123(US9290485, 155)
Affinity DataIC50: 3nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212137(US9290485, 169)
Affinity DataIC50: 3nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212043(US9290485, 75)
Affinity DataIC50: 3.10nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212083(US9290485, 115)
Affinity DataIC50: 3.30nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212120(US9290485, 152)
Affinity DataIC50: 4nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212126(US9290485, 158)
Affinity DataIC50: 4nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212129(US9290485, 161)
Affinity DataIC50: 4nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212108(US9290485, 140)
Affinity DataIC50: 4.60nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212107(US9290485, 139)
Affinity DataIC50: 4.90nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212130(US9290485, 162)
Affinity DataIC50: 5nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212131(US9290485, 163)
Affinity DataIC50: 5nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212057(US9290485, 89)
Affinity DataIC50: 6nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212133(US9290485, 165)
Affinity DataIC50: 6nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212127(US9290485, 159)
Affinity DataIC50: 7nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212117(US9290485, 149)
Affinity DataIC50: 7.80nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM211991(US9290485, 23)
Affinity DataIC50: 9nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212008(US9290485, 40)
Affinity DataIC50: 9nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212099(US9290485, 131)
Affinity DataIC50: 9nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212138(US9290485, 170)
Affinity DataIC50: 9.70nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212118(US9290485, 150)
Affinity DataIC50: 10nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212031(US9290485, 63)
Affinity DataIC50: 11nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212119(US9290485, 151)
Affinity DataIC50: 13nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212032(US9290485, 64)
Affinity DataIC50: 14nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212095(US9290485, 127)
Affinity DataIC50: 16nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212121(US9290485, 153)
Affinity DataIC50: 16nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212051(US9290485, 83)
Affinity DataIC50: 18nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM211994(US9290485, 26)
Affinity DataIC50: 19nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212006(US9290485, 38)
Affinity DataIC50: 19nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212128(US9290485, 160)
Affinity DataIC50: 20nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM211995(US9290485, 27)
Affinity DataIC50: 21nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212104(US9290485, 136)
Affinity DataIC50: 24nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Novartis

US Patent
LigandPNGBDBM212139(US9290485, 171)
Affinity DataIC50: 26nMpH: 7.8 T: 2°CAssay Description:Enzymatic reactions were conducted in assay buffer , comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For the det...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2017
Entry Details
Go to US Patent

Displayed 1 to 50 (of 183 total ) | Next | Last >>
Jump to: